Compare Mesoblast Limited (MESO) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.9. The key difference: Mesoblast Limited is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| MESO | SJNK | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $20.96 | $25.63 |
52-Week Low | $12.88 | $24.75 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $36 million for Ryoncil, showing strong commercial progress, but maintains a net income margin of -144.33% with significant losses. Recent news highlights pivotal Phase 3 trial milestones for chronic low back pain treatment and a $50 million non-dilutive financing draw.
Outlook is mixed: bullish analyst sentiment and clinical advancements offer upside potential, but high cash burn and persistent losses pose substantial risks. Investors should weigh the company's growth trajectory against its financial sustainability and regulatory milestones.
SJNK trades at $24.92 with no change over the past 24 hours, reflecting stability amid a bearish technical signal from moving averages. The ETF maintains a neutral stance in oscillators, with RSI levels indicating neither overbought nor oversold conditions. Recent corporate actions include scheduled dividend payments, with H2-26 set at $0.15 per share. Institutional activity shows Balefire LLC reduced its stake by 74.7% in the latest quarter, as per SEC filings dated 2026-07-21.
The outlook for SJNK is cautious due to bearish technical indicators and negative sentiment from analysts, who rate it SELL citing exhausted tailwinds from falling yields. Risks include high sensitivity to interest rate changes and credit spread volatility. Investment opportunity lies in its high-yield bond focus, but current conditions suggest limited near-term upside amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
